RCM
KLRS

RA Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

RA Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-62,632
Closed -$9.72M – 102
2022
Q1 		$9.72M Buy
+62,632
New +$12.5M 0.21% 78

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

RA Capital Management's KLRS Position: Q2 2022 in Review

RA Capital Management sold out of Kalaris Therapeutics (KLRS) in Q2 2022, closing a stake of 62,632 shares — an estimated $9.72M sold.

RA Capital Management first reported a position in KLRS in Q1 2022 and held it in 1 quarter. The position peaked at $9.72M in Q1 2022. 84 funds tracked by Wall St. Rank hold KLRS as of Q2 2022.

  • RA Capital Management reported no remaining Kalaris Therapeutics position as of Q2 2022 after selling out during the quarter.
  • RA Capital Management sold 62,632 Kalaris Therapeutics shares in Q2 2022, an estimated $9.72M.
  • RA Capital Management first reported a position in Kalaris Therapeutics in Q1 2022 and held it in 1 quarter.
  • RA Capital Management's Kalaris Therapeutics position peaked at $9.72M in Q1 2022.
  • 84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2022.

Based on RA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.